切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (05) : 377 -381. doi: 10.3877/cma.j.issn.1674-1358.2019.05.006

所属专题： 文献；

论著

经联合抗反转录病毒治疗的因献血感染人类免疫缺陷病毒者肝病相关死亡分析
杨蓉蓉1, 桂希恩1,†(), 熊勇1, 高世成1   
  1. 1. 430071　武汉市，武汉大学中南医院感染科
  • 收稿日期:2019-02-15 出版日期:2019-10-15
  • 通信作者: 桂希恩
  • 基金资助:
    湖北省卫生计生青年人才项目(No. WJ2015Q019)

Analysis of liver-related mortality among human immunodeficiency virus infected patients after blood donation who received combined antiretroviral therapy

Rongrong Yang1, Xien Gui1,†(), Yong Xiong1, Shicheng Gao1   

  1. 1. Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  • Received:2019-02-15 Published:2019-10-15
  • Corresponding author: Xien Gui
  • About author:
    Corresponding author: Gui Xien, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

杨蓉蓉, 桂希恩, 熊勇, 高世成. 经联合抗反转录病毒治疗的因献血感染人类免疫缺陷病毒者肝病相关死亡分析[J]. 中华实验和临床感染病杂志(电子版), 2019, 13(05): 377-381.

Rongrong Yang, Xien Gui, Yong Xiong, Shicheng Gao. Analysis of liver-related mortality among human immunodeficiency virus infected patients after blood donation who received combined antiretroviral therapy[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(05): 377-381.

目的

探讨联合抗反转录病毒治疗（cART）对既往因献血感染人类免疫缺陷病毒（HIV）者肝病相关病死率的影响。

方法

收集2003年1月至2015年12月武汉大学中南医院诊治的940例既往因献血感染HIV者的性别、年龄、诊断时间、治疗情况、死亡日期和主要死因等资料，回顾性分析638例行cART死亡患者（cART治疗组）和302例未行cART死亡患者（未治疗组）的肝病相关死亡影响因素。

结果

cART治疗组患者总体病死率为33.9%（216/638），显著低于未治疗组（93.4%、282/302），差异有统计学意义（χ2 = 291.511、P < 0.001）；但cART治疗组肝病相关病死率为7.8%（50/638），显著高于未治疗组（4.0%、12/302），差异有统计学意义（χ2 = 4.966、P = 0.026）。其中，cART治疗组患者丙型肝炎病毒感染相关病死率和死亡比例分别为7.1%（45/638）和20.8%（45/216），均显著高于未治疗组[2.6%（8/302）和2.8%（8/282）]，差异有统计学意义（χ2 = 7.473、P = 0.006，χ2 = 41.655、P < 0.001）。

结论

在既往因献血感染HIV人群中，cART可降低其总体病死率，但HCV感染相关病死率增加。

关键词: 人类免疫缺陷病毒, 联合抗反转录病毒治疗, 病死率, 肝病
Objective

To investigate the effect of combined antiretroviral therapy (cART) on liver-related mortality among human immunodeficiency virus (HIV)-infected patients after blood donation.

Methods

From January 2003 to December 2015, gender, age, diagnosis point, treatment status, date of death, main causes of death and other information of 940 patients with acquired immunodeficiency syndrome (AIDS) were collected. The factors influencing the related death of liver disease of 638 patients with cART (cART treated group) and 302 untreated patients (untreated group) were analyzed, retrospectively.

Results

The overall mortality of patients in cART treated group was 33.9% (216/638), which was significantly lower than that in untreated group (93.4%, 282/302), with significant difference (χ2 = 291.511, P < 0.001). However, the mortality of liver disease of patients in cART group was 7.8% (50/638), significantly higher than that in untreated group (4.0%, 12/302), with significant difference (χ2 = 4.966, P = 0.026). The mortality and fatality rates of hepatitis C virus infection of patients in cART group were 7.1% (45/638) and 20.8% (45/216), which were significantly higher than those in untreated group [2.6% (8/302) and 2.8% (8/282)], with significant differences (χ2 = 7.473, P = 0.006; χ2 = 41.655, P < 0.001).

Conclusions

In previous HIV-infected people, cART could reduce the overall case-fatality rate, but the mortality associated with HCV infection increased.

Key words: Human immunodeficiency virus, Combination antiretroviral therapy, Mortality, Liver diseases
表1 cART治疗和未治疗组患者的一般资料
组别 例数 男性[例（%）] 年龄（±s，岁） HBsAg阳性[例（%）] 抗-HCV阳性[例（%）] HCV RNA检测例数 HCV RNA阳性[例（%）]
cART治疗组 638 462（72.4） 53.8 ± 3.78 62（9.7） 555（87.0） 500 372（74.4）
未治疗组 302 218（72.2） 54.6 ± 8.20 29（9.6） 266（88.1） 240 180（75.0）
统计量 ? χ2 = 0.005 t = 0.193 χ2 = 0.003 χ2 = 0.220 — χ2 = 0.031
P值 ? 0.942 0.847 0.956 0.639 — 0.861
表2 cART治疗组和未治疗组患者总体病死率和肝病相关病死率[例（%）]
组别 例数 总病死率a 肝病相关病死率b
HBV感染相关c HCV感染相关d
cART治疗组 638 216（33.9） 5（0.8） 45（7.1）
未治疗组 302 282（93.4） 4（1.3） 8（2.6）
χ2值 ? 291.511 0.632 7.473
P值 ? < 0.001 0.427 0.006
表3 cART治疗组和未治疗组各类型肝病相关死亡比例[例（%）]
组别 总例病死数 肝病相关死亡 按终末期肝病临床类型分类 按肝炎病毒分类
肝硬化a 原发性肝癌b 肝功能衰竭 HBV相关 HCV相关
cART治疗组 216 50（23.1） 34（15.7） 14（6.5） 2（0.9） 5（2.3） 45（20.8）
未治疗组 282 12（4.3） 6（2.1） 4（1.4） 2（0.7） 4（1.4） 8（2.8）
χ2值 ? 40.054 30.685 9.000 0.072 0.554 41.655
P值 ? < 0.001 < 0.001 0.003 0.788 0.457 < 0.001
[1]
张福杰主编. 国家免费艾滋病抗病毒药物治疗手册[M]. 2版. 北京: 人民卫生出版社,2008:15.
[2]
豆智慧,赵燕,何云, 等. 免费抗病毒治疗降低获得性免疫缺陷综合征患者病死率回顾性队列研究[J]. 中华预防医学杂志,2009,43(12):1091-1095.
[3]
薛子东,卫军,原琛利, 等. 山西省艾滋病免费ART病例治疗效果分析[J]. 中国艾滋病性病,2014,20(9):641-644.
[4]
Palella FJ Jr,Baker RK,Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study[J]. J Acquir Immune Defic Syndr,2006,43(1):27-34.
[5]
Zhang F,Dou Z,Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: A national observational cohort study[J]. Lancet Infect Dis,2011,11(7):516-524.
[6]
王璐,秦倩倩,丁正伟, 等. 2010年中国艾滋病疫情网络直报现状与分析[J]. 中国艾滋病性病,2011,17(3):275-278.
[7]
Waldrep TW,Summers KK,Chiliade PA. Coinfection with HIV and HCV: more questions than answers[J]. Pharmacotherapy,2000,20(12):1499-1507.
[8]
Yang RR,Gui XE,Gao SC, et al. Interaction of hepatitis B and C viruses in patients infected with HIV[J]. J Acquir Immune Defic Syndr,2008,48(4):491-492.
[9]
Seeff LB,Hoofnagle JH. Appendix:the national institutes of health consensus development conference management of hepatitis C 2002[J]. Clin Liver Dis,2003,7(1):261-287.
[10]
Lo Re V 3rd,Newcomb CW,Carbonari DM, et al. Determinants of liver complications among HIV/hepatitis B virus-coinfected patients[J]. J Acquir Immune Defic Syndr,2019,82(1):71-80.
[11]
Chireshe R,Naidoo K,Nyamakura R. Hypertension among human immunodeficiency virus infected patients on treatment at Parirenyatwa Hospital: A descriptive study[J]. Afr J Prim Health Care Fam Med,2019,11(1):e1-e8.
[12]
Albrecht S,Franzeck FC,Mapesi H, et al. Age-related comorbidities and mortality in people living with HIV in rural Tanzania[J]. AIDS,2019,33(6):1031-1041.
[13]
Franzetti M,Ricci E,Bonfanti P. The pattern of non-AIDS-defining cancers in the HIV population: epidemiology, risk factors and prognosis. A review[J]. Curr HIV Res,2019,17(1):1-12.
[14]
So-Armah K,Freiberg MS. HIV and cardiovascular disease: Update on clinical events, special populations, and novel biomarkers[J]. Curr HIV/AIDS Rep,2018,5(3):233-244.
[15]
Oliveira RVC,Shimakura SE,Campos DP, et al. Effects of antiretroviral treatment and nadir CD4 count in progression to cardiovascular events and related comorbidities in a HIV Brazilian cohort: a multi-stage approach[J]. AIDS Care,2018,30(5):551-559.
[16]
Durand M,Chartrand-Lefebvre C,Baril JG, et al. The Canadian HIV and aging cohort study--determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol[J]. BMC Infect Dis,2017,17(1):611.
[17]
Rasmussen LD,May MT,Kronborg G, et al. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study[J]. Lancet HIV,2015,2(7):e288-298.
[18]
Zheng H,Wang L,Huang P, et al. Incidence and risk factors for AIDS-related mortality in HIV patients in China: a cross-sectional study[J]. BMC Public Health,2014,14:831.
[19]
Zhang F,Dou Z,Yu L, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China[J]. Clin Infect Dis,2008,47(6):825-833.
[20]
Benzaken AS,Girade R,Catapan E, et al. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach[J]. Braz J Infect Dis,2019,23(3):182-190.
[21]
Kronfli N,Bhatnagar SR,Hull MW, et al. Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up[J]. AIDS,2019,33(6):1013-1022.
[22]
Billa O,Chalouni M,Salmon D, et al. Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort[J]. PLoS One,2018,13(12):e0208657.
[23]
Bruden DJT,McMahon BJ,Townshend-Bulson L, et al. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort[J]. Hepatology,2017,66(1):37-45.
[24]
Brož J. Screening of diabetes mellitus among people living with HIV[J]. J Int AIDS Soc,2019,22(6):e25335.
[25]
Han WM,Jiamsakul A,Kiertiburanakul S, et al. Diabetes mellitus burden among people living with HIV from the Asia-Pacific region[J]. J Int AIDS Soc,2019,22(1):e25236.
[1] 刘婷婷, 林妍冰, 汪珊, 陈幕荣, 唐子鉴, 代东伶, 夏焙. 超声衰减参数成像评价儿童代谢相关脂肪性肝病的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 787-794.
[2] 万欣, 贺秋霞, 李明明, 王守志, 陈曦, 杨秀华. 超声衰减成像技术评价肝脂肪变性的相关因素分析[J]. 中华医学超声杂志（电子版）, 2023, 20(01): 57-62.
[3] 吴茜, 邓力, 练士贤, 张华, 江颖, 张宏伟. 伴人类免疫缺陷病毒感染乳腺癌患者的临床病理特征与预后的相关性研究[J]. 中华乳腺病杂志(电子版), 2023, 17(03): 151-156.
[4] . 肝移植治疗终末期肝病[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 1-.
[5] 陈婧, 姚杨, 苗继荣, 丁格, 马青, 彭伊梦, 卢洲, 康凤尔, 王胜昱. 静脉-动脉体外膜肺氧合联合主动脉内球囊反搏对心源性疾病患者病死率的影响：Meta分析[J]. 中华危重症医学杂志(电子版), 2023, 16(01): 48-59.
[6] 张玉, 薛文瑞, 王鑫, 李旭瑜, 王旭东, 袁鹏飞, 梁雨润, 韩志兴, 张海建, 刘庆军, 纪世琪. 人类免疫缺陷病毒感染合并膀胱癌14例临床特点[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 354-358.
[7] 崔贵香, 丁晓燕, 褚盈晖, 孙代, 吴海燕, 陈京龙. 57例人类免疫缺陷病毒感染合并Burkkit淋巴瘤患者的临床分析[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(02): 102-109.
[8] 袁瑞, 胡文佳, 桂希恩, 严亚军, 冯玲, 柯亨宁, 熊勇, 杨蓉蓉. 淋巴细胞精细分型检测在人类免疫缺陷病毒感染者/获得性免疫缺陷综合征患者中的应用[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(02): 84-91.
[9] 李倩, 邓莉平, 陈果, 张忠威, 莫平征, 胡文佳, 陈良君, 张捷, 张永喜, 杨蓉蓉, 熊勇. 宏基因组二代测序在获得性免疫缺陷综合征合并中枢神经系统感染中的临床应用[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 24-31.
[10] 汤艳芬, 赵雯, 马成杰, 刘刚, 陈奇, 刘菁, 薛天娇, 刘岩岩, 陈融佥, 王宇. 人类免疫缺陷病毒感染合并鸟分枝杆菌复合群病临床特点[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(05): 348-353.
[11] 张燕珍, 王锡携, 文小兰. 血清巨噬细胞迁移抑制因子对活动性肺结核分诊检测的意义[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 200-202.
[12] 王希岗, 张波, 李鸣, 高敏, 薛建新. 神经外科手术部位感染在HIV感染者与非HIV感染者中的临床差异[J]. 中华神经创伤外科电子杂志, 2023, 09(04): 228-233.
[13] 朱国英, 陈利, 舍玲, 白洁, 丁永年, 朱风尚. 微生态调节剂治疗非酒精性脂肪性肝病的现状和困境[J]. 中华消化病与影像杂志(电子版), 2023, 13(01): 1-4.
[14] 张大涯, 陈世锔, 陈润祥, 张晓冬, 李达, 白飞虎. 肠道微生物群对代谢相关脂肪性肝病发展的影响[J]. 中华临床医师杂志(电子版), 2023, 17(07): 828-833.
[15] 赵宁, 陈娟媚, 杨其霖, 莫沛. 急性心肌梗死患者住院病死率和纤维蛋白原水平的非线性关系[J]. 中华临床实验室管理电子杂志, 2023, 11(01): 32-37.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号